Welcome to our dedicated page for Glaukos Corporation news (Ticker: GKOS), a resource for investors and traders seeking the latest updates and insights on Glaukos Corporation stock.
Glaukos Corporation (NYSE: GKOS) is a prominent ophthalmic medical technology company specializing in breakthrough products and procedures aimed at transforming the treatment of glaucoma. As one of the leading causes of blindness globally, glaucoma demands innovative solutions, and Glaukos has pioneered micro-invasive glaucoma surgery (MIGS) to revolutionize traditional management paradigms.
The company's flagship product, the iStent Trabecular Micro-Bypass Stent, launched in the United States in 2012, is celebrated for being the smallest medical device ever approved by the FDA, measuring a mere 1.0 mm long and 0.33 mm wide. This device is designed to reduce intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma when used in conjunction with cataract surgery.
Building on the success of the iStent, Glaukos is developing a comprehensive and proprietary portfolio of injectable micro-scale therapies targeting the entire spectrum of glaucoma disease states and progression. The pipeline includes the iStent SA Trabecular Micro-Bypass System, a two-stent product with a different auto-injection inserter for standalone procedures.
In June 2015, Glaukos successfully completed its initial public offering, and its shares are now publicly traded on the New York Stock Exchange. The company continues to innovate and expand its product offerings, maintaining its position as a leader in the ophthalmic medical technology field.
- Recent achievements include the expansion of their product pipeline and the ongoing development of next-generation MIGS devices.
- Current projects focus on enhancing the efficacy and accessibility of glaucoma treatments worldwide.
- Partnerships with leading ophthalmic institutions and research organizations fuel Glaukos' mission to improve patient outcomes.
Glaukos Corporation remains committed to transforming glaucoma treatment through technological innovation and strategic growth.
Glaukos Corporation (NYSE: GKOS), a leader in ophthalmic medical technology, has announced its management will participate in the Wells Fargo Healthcare Conference on September 7, 2022, at 3:45 p.m. ET in Boston, MA. This event will highlight Glaukos' focus on novel therapies for treating glaucoma, corneal disorders, and retinal diseases. A live webcast will be available in the Investors section of the Glaukos website.
iVeena Delivery Systems has entered a strategic licensing agreement with Glaukos Corporation (NYSE: GKOS) for exclusive global rights to IVMED-80, a treatment for keratoconus, a rare corneal disorder. IVMED-80 is a proprietary topical eye drop that has shown promising results in a phase 1/2a clinical study, achieving a significant reduction in corneal curvature. Glaukos paid $10 million upfront for the license and will cover all development costs, with further milestone payments and royalties possible. This partnership aims to enhance treatment options for keratoconus patients.
Glaukos Corporation (NYSE: GKOS) has received 510(k) clearance from the U.S. FDA for its iStent infinite Trabecular Micro-Bypass System, the first micro-invasive implantable device approved for standalone glaucoma treatment. This innovative device features a three-stent system designed to lower intraocular pressure (IOP) by restoring natural fluid outflow. CEO Thomas Burns highlighted the device's potential, backed by compelling clinical data. Initial commercial launch activities for iStent infinite are planned for later this year.
Glaukos Corporation (NYSE: GKOS) reported Q2 2022 net sales of $72.7 million, a decrease from $78.1 million in Q2 2021. Key segments included $56.1 million from glaucoma and $16.6 million from corneal health. Gross margin was approximately 75%, down from 77% year-over-year. Notably, R&D expenses surged 31% to $31.7 million. Glaukos raised its full-year revenue guidance to $275 million to $280 million, up from $270 million to $275 million. The company ended the quarter with approximately $400 million in cash and equivalents.
Glaukos Corporation (NYSE: GKOS) is scheduled to release its Q2 2022 financial results after the market closes on August 3, 2022. The management will hold a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET) on the same day to discuss the results. Investors can access the live webcast on the company's website. Glaukos focuses on innovative therapies for treating glaucoma, corneal disorders, and retinal diseases, having pioneered Micro-Invasive Glaucoma Surgery (MIGS) since 2012.
Glaukos Corporation (NYSE: GKOS) announced its participation in the William Blair 42nd Annual Growth Stock Conference scheduled for June 8, 2022, at 8:40 a.m. CT in Chicago, IL. The event will feature a live and archived webcast available on the company's investor relations website. Glaukos focuses on innovative ophthalmic medical technologies targeting glaucoma, corneal disorders, and retinal diseases, having pioneered Micro-Invasive Glaucoma Surgery (MIGS) with its first device launched in 2012. The company continues to advance treatment options in these areas through ongoing innovations.
Glaukos Corporation (NYSE: GKOS) announced its virtual participation in the Piper Sandler Ophthalmology Symposium on May 23, 2022, at 2:00 p.m. ET. The company is focused on innovative therapies for glaucoma, corneal disorders, and retinal diseases. Glaukos pioneered Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to traditional treatments, launching its first MIGS device in 2012. The event will feature a live and archived webcast accessible through the Glaukos Investors section.
Glaukos Corporation (NYSE: GKOS) reported Q1 2022 financial results, with net sales of $67.7 million, slightly down from $68.0 million in Q1 2021. Glaucoma sales accounted for $51.5 million, while Corneal Health contributed $16.1 million. The gross margin was approximately 75%, and operating expenses increased to $40.8 million. The company reported a net income of $5.4 million ($0.11 per diluted share), compared to a net loss of $16.5 million in the same period last year. Glaukos updated its 2022 net sales guidance to $270 million - $275 million.
Glaukos Corporation (NYSE: GKOS), a leader in ophthalmic medical technology, will present its innovative products at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting from April 22-26, 2022, in Washington, D.C. Glaukos is sponsoring an educational symposium titled “Expanding Your Treatment Algorithm: New, Innovative Product Portfolio from Glaukos” on April 22 at 5:30 PM, featuring notable experts. Key presentations will include findings on the Trabecular Micro-Bypass Stent and other advancements in glaucoma and corneal health therapies, enhancing their market presence and potential future growth.
FAQ
What is the current stock price of Glaukos Corporation (GKOS)?
What is the market cap of Glaukos Corporation (GKOS)?
What is Glaukos Corporation?
What is the iStent Trabecular Micro-Bypass Stent?
When did Glaukos go public?
What is MIGS?
What is the iStent SA?
What recent achievements has Glaukos made?
What is the significance of Glaukos' products?
Who are Glaukos' partners?
What is Glaukos' mission?
How does Glaukos continue to innovate?
